| 一线阿法替尼与化疗对EGFR突变伴有脑转移的非小细胞肺癌患者的疗效评价 |
| |
| 引用本文： | 潘燚,谭佩欣. 一线阿法替尼与化疗对EGFR突变伴有脑转移的非小细胞肺癌患者的疗效评价[J]. 循证医学, 2016, 16(4): 230-232. DOI: 10.12019/j.issn.1671-5144.2016.04.012 |
| |
| 作者姓名： | 潘燚 谭佩欣 |
| |
| 作者单位： | 广东省人民医院肿瘤中心放疗科、广东省医学科学院, 广州510080 |
| |
| 摘 要： | 1文献来源Schuler M,Wu YL,Hirsh V,et al.First-lineAfatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growthfactor receptor gene mutations and brain metastases[J].J Thorac Oncol,2016,11(3):380-390.2证据水平2a。3背景EGFR阳性的非小细胞肺癌(non-small celllung cancer,NSCLC)出现脑转移的概率高达44%~63%,但目前极少有针对此类患者的前瞻性临床研究。部分研究表明阿法替尼可通过血脑屏障控制
|
| 关 键 词： | 非小细胞肺癌 脑转移 EGFR突变 阿法替尼 |
First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases |
| |
| PAN Yi;TAN Pei-xin. First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. The Journal of Evidence-Based Medicine, 2016, 16(4): 230-232. DOI: 10.12019/j.issn.1671-5144.2016.04.012 |
| |
| Authors: | PAN Yi TAN Pei-xin |
| |
| Affiliation: | Authors’address： Department of Radiotherapy, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | non-small cell lung cancer brain metastases EGFR gene mutations Afatinib |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
|
